Biotoscana to buy United Medical to create regional specialty pharma group in South America

14 January 2014

Colombia-based Grupo Biotoscana has signed an agreement to acquire Brazilian drugmaker United Medical to create a leading specialty pharmaceutical company with commercialization capabilities throughout South America.

The acquisition, the financial terms of which have noted been disclosed but will be financed by Biotoscana’s majority shareholders Advent International and Essex Woodlands, will broaden Biotoscana’s portfolio of innovative licensed products as well as its geographic sales and marketing capabilities by expanding into the $28 billion Brazilian pharmaceutical market.

The transaction, which is subject to customary closing conditions, including Brazilian antitrust regulatory approval, is expected to close in the first quarter of 2014.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK